PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

医学 内科学 易普利姆玛 舒尼替尼 临床终点 无容量 贝伐单抗 肿瘤科 随机化 临床试验 癌症 依维莫司 卡波扎尼布 免疫疗法 化疗
作者
Tian Zhang,Karla V. Ballman,Atish D. Choudhury,Ronald C. Chen,Colleen Watt,Yujia Wen,Ardaman Shergill,Tyler Zemla,Hamid Emamekhoo,Ulka N. Vaishampayan,Michael J. Morris,Daniel J. George,Toni K. Choueiri
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (6_suppl): TPS366-TPS366 被引量:20
标识
DOI:10.1200/jco.2021.39.6_suppl.tps366
摘要

TPS366 Background: First-line treatment of mRCC has rapidly changed to include IPI-NIVO or CABO, with clinical benefit of each based on the Checkmate 214 and CABOSUN (A031203) trials. Combination immunotherapy with VEGF therapies has shown benefit over sunitinib in the JAVELIN 101 and KEYNOTE 426 trials. It is yet unclear which patients (pts) benefit most from combination immunotherapy-VEGF inhibitors, and the optimal sequence of drugs. Methods: In an adaptive, randomized, multicenter phase III trial (Alliance A031704, PDIGREE), pts start treatment with induction IPI 1 mg/kg and NIVO 3 mg/kg intravenously (IV) once every 3 weeks. Key inclusion criteria include clear cell mRCC, International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk, Karnofsky performance status >70, and no prior treatments for mRCC. Based on 3-month radiographic assessment (after completing IPI-NIVO combination), pts with complete responses (CR) undergo maintenance NIVO 480 mg IV every 4 weeks; pts with progression of disease (PD) switch to CABO 60 mg oral daily; pts with non-CR/non-PD are randomized to NIVO 480 mg IV every 4 weeks versus NIVO 480 mg IV every 4 weeks with CABO 40 mg oral daily. Randomization is stratified by IMDC risk criteria and presence of bone metastases. The primary endpoint of the study is overall survival (OS). We hypothesize that 3-year OS will improve to 70% for NIVO-CABO compared to 60% for NIVO alone; to achieve 85% power with a two-sided alpha of 0.05 and exponential distribution, 696 patients will be randomized. Accounting for 30% patients with either CR or PD, and 5% dropout from toxicity, up to 1046 pts will be enrolled. Key secondary endpoints include progression-free survival, 12-month CR rate, overall response rate based on RECIST 1.1 and iRECIST criteria, and toxicity profiles. Quality of life will be assessed based on the FKSI-19, PROMIS-fatigue, and EQ5D-5L questionnaires. Biomarkers associated with CR, tissue-based and plasma-based biomarkers will be assessed. Updated enrollment through January 2021 will be presented. Clinical trial information: NCT03793166 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拾壹完成签到,获得积分10
6秒前
雪花完成签到,获得积分10
8秒前
清风完成签到 ,获得积分10
8秒前
雪花发布了新的文献求助10
12秒前
秀丽笑容完成签到 ,获得积分10
16秒前
江湖应助聪慧芷巧采纳,获得10
17秒前
量子星尘发布了新的文献求助10
18秒前
Rjy完成签到 ,获得积分10
24秒前
性感母蟑螂完成签到 ,获得积分10
30秒前
ruochenzu完成签到,获得积分10
32秒前
陈尹蓝完成签到 ,获得积分10
33秒前
天道酬勤完成签到,获得积分10
35秒前
37秒前
仁爱的谷南完成签到,获得积分10
37秒前
雯雯完成签到 ,获得积分10
39秒前
一路有你完成签到 ,获得积分10
39秒前
40秒前
ruochenzu发布了新的文献求助10
40秒前
42秒前
wanghao完成签到 ,获得积分10
43秒前
图图发布了新的文献求助10
43秒前
十三完成签到 ,获得积分10
43秒前
聪慧芷巧完成签到,获得积分10
44秒前
米博士完成签到,获得积分10
45秒前
研友_VZGVzn完成签到,获得积分10
46秒前
Cheung2121发布了新的文献求助30
47秒前
黄芩完成签到 ,获得积分10
48秒前
1分钟前
秋半梦完成签到,获得积分10
1分钟前
李爱国应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
搜集达人应助科研通管家采纳,获得10
1分钟前
打地鼠工人完成签到,获得积分10
1分钟前
彩色半烟完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
Ning完成签到,获得积分10
1分钟前
图图完成签到,获得积分10
1分钟前
勤奋的灯完成签到 ,获得积分10
1分钟前
ludong_0完成签到,获得积分10
1分钟前
Asumita完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022